Clinical Trials Logo

Unresectable Stage III NSCLC clinical trials

View clinical trials related to Unresectable Stage III NSCLC.

Filter by:
  • None
  • Page 1

NCT ID: NCT04982549 Recruiting - Clinical trials for Unresectable Stage III NSCLC

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

NCT ID: NCT04381494 Terminated - Clinical trials for Unresectable Stage III NSCLC

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

ON TRAX
Start date: April 27, 2020
Phase: Phase 4
Study type: Interventional

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

NCT ID: NCT04161352 Not yet recruiting - Clinical trials for Unresectable Stage III NSCLC

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

R-helper
Start date: November 25, 2019
Phase:
Study type: Observational

The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.